Salute e Benessere

Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC

Regulated InformationLeuven, BELGIUM, Boston, MA, US – August 4 , 2023 – 7 .00PM CETOxurion NV (Euronext Brussels: OXUR) a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, today announced that, pursuant to Belgian Transparency legislation 1it has received a transparency notification as follows: Oxurion received a transparency notification on August 2, 2023,...
Nasdaq GlobeNewswire
04/08/2023

Ipsen - Monthly information relative to the total number of voting rights and…

Monthly information relative to the total number of voting rightsand shares composing the share capital(in accordance with Article L.233-8 II of the French Commercial Code andArticle 223-16 of the General Regulation of theAutorité des Marchés Financiers ) Market: Euronext ParisISIN Code: FR 0010259150 LEI: 549300M6SGDPB4Z94P11 DateTotal number of shares composing the share capitalTotal number of voting rights(1)31 July 202383,814,526Gross total* of...
Nasdaq GlobeNewswire
04/08/2023

Groupe Casino - Nombre de droits de vote et d'actions au 31-07-2023

CASINO, GUICHARD-PERRACHON Société anonyme au capital de 165 892 131,90 € Siège social : 1, Cours Antoine Guichard 42000 Saint-Etienne 554 501 171 R.C.S. Saint-Etienne Informations relatives au nombre total de droits de vote et d'actions composant le capital social au 31 juillet 2023(article 223-16 du Règlement Général de l'Autorité des Marchés Financiers) Nombre d'actions composant le capitalNombre total de droits de voteNombre total de droits de vote...
Nasdaq GlobeNewswire
04/08/2023

Understanding ACL Reconstruction Procedures: Advancements and Market Trends - By…

There are two main types of ACL reconstruction procedures: extra-articular and intra-articular. Extra-articular procedures are situated outside the joint and are often used to address fractures that do not extend into the joint. On the other hand, intra-articular procedures focus on repairing the ligament within the joint, addressing the torn ACL directly. These procedures involve various fixation types, including femoral and tibial fixation, and are performed in various healthcare settings such…
PR Newswire
04/08/2023

Biosensors Market size worth $ 54.20 Billion, Globally, by 2030 at 8.55% CAGR…

Download PDF Brochure: https://www.verifiedmarketresearch.com/download-sample?rid=33493 Download PDF Brochure: https://www.verifiedmarketresearch.com/download-sample?rid=33493 Browse in-depth TOCon" Biosensors Market " 202 - Pages 126 – Tables 37 – Figures The market for biosensors worldwide is expanding and exhibiting strong growth due to technological advancements. Due to major technological breakthroughs and a wide range of applications across numerous...
PR Newswire
04/08/2023

DFS' BIGGEST BEAUTY EVENT OF THE YEAR INVITES CUSTOMERS TO EXPLORE NEW…

Guerlain and Jo Malone London Anchor the Extensive List of Participating Luxury Beauty Brands Guerlain and Jo Malone London Anchorthe Extensive List of Participating Luxury Beauty Brands Two anchor brands,Guerlain and Jo Malone London, will be joined by Burberry,Charlotte Tilbury, Clarins, Clinique, Estée Lauder, Ginza, Kiehl's, La Mer, Lancôme, L'Occitane,Sol de Janeiroand Sulwhasoo to offer a variety of pop-ups* and at-counter* experiences. Customers will be invited to...
PR Newswire
04/08/2023

Oncolytics Biotech® to Participate in a Fireside Chat at Canaccord Genuity's…

Date: Thursday, August 10, 2023 Time: 12:00 p.m. ET Location:InterContinentalBoston, Abigail Adams C Room Webcast Link:Available byclicking here Company management will also be participating in one-on-one investor meetings at the conference. To schedule a meeting, please submit a request on the conference website, contact your Canaccord representative, or emailjpatton@oncolytics.ca. A live webcast of the Company's presentation will also be available...
PR Newswire
04/08/2023

Innocan Pharma Announces Closing of Private Placement

Each Class A Warrant will entitle the holder thereof to purchase one Common Share at a price of C$0.29 for a period of three (3) years from the date of issuance. Each Class B Warrant will entitle the holder thereof to purchase one Common Share at a price of C$0.40 for a period of five (5) years from the date of issuance. Each Class A Warrant will entitle the holder thereof to purchase one Common Share at a price ofC$0.29for a period of three (3) years from the date of issuance. Each Class B...
PR Newswire
04/08/2023

AC Immune Reports Second Quarter 2023 Financial Results and Provides a Corporate…

AC ImmuneReports Second Quarter 2023 Financial Results and Provides a Corporate UpdateReceived FDA Fast Track Designation for ACI-24.060 anti-amyloid-beta (Abeta) active immunotherapy to treat Alzheimer's disease (AD)Enrollment in ongoing Phase 1b/2 ABATE study of ACI-24.060 in AD and Down syndrome (DS) is on track and expanding to sites in USA following IND clearance, dosed first individual with DSNext interim safety and immunogenicity data from AD and DS cohorts in ABATE...
Nasdaq GlobeNewswire
04/08/2023

Ultrasound Market worth $11.6 billion | MarketsandMarkets

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=467 Download an Illustrative overview:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=467 Browse in-depth TOC on "Ultrasound Market" 179 - Tables 39 - Figures257 - Pages Ultrasound Market Scope: Technology segment to register significant growth rate over the forecast period of 2023-2028 Based on technology, the global ultrasound imaging market is segmented into...
PR Newswire
04/08/2023

ACCORD and HIPRA Enter into Exclusive Distribution Agreement to Commercialise…

"We are delighted to collaborate with HIPRA to make available a recombinant protein based COVID-19 vaccine in the United Kingdom, this provides an additional option to help to combat what is still a health threat." said Paul Tredwell, Executive Vice President of Accord Healthcare Ltd. "We are delighted to collaborate with HIPRA to make available a recombinant protein based COVID-19 vaccine in theUnited Kingdom, this provides an additional option to help to combat what is still a…
PR Newswire
04/08/2023

Basilea announces submission of a New Drug Application to the US Food and Drug…

Seeking approval forStaphylococcus aureusbacteremia (SAB) , acute bacterial skin and skin structure infections (ABSSSI) , and community-acquired bacterial pneumonia (CABP)NDA eligible for Priority Review Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, August 04 , 2023 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and...
Nasdaq GlobeNewswire
04/08/2023

Addex Therapeutics to Release Half-Year 2023 Financial Results and Host…

Geneva, Switzerland, August3 , 2023–Addex Therapeutics(SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that it will issue its Half-Year 2023 Financial Results on August 10, 2023. Tim Dyer, CEO,Robert Lütjens, Head of Discovery – Biology and Mikhail Kalinichev, Head of Translational Science, will provide a business update and a review of the Addex product pipeline during a...
Nasdaq GlobeNewswire
04/08/2023

Piramal Pharma Limited Announces Consolidated Results for Q1FY24

# Q1 FY23 EBITDA had one-time inventory margin impact of INR68 Crore Key Highlights for Q1FY24 Nandini Piramal, Chairperson, Piramal Pharma Limited said, " We had a positive start to the new financial year with healthy revenue growth and improvement in our EBITDA margins. Our CDMO business is also witnessing continued order inflows, especially for our differentiated offerings and innovation related work. Our Inhalation Anesthesia portfolio is seeing a healthy demand and our...
PR Newswire
04/08/2023

Pancreatic Endocrine Tumor Market is Expected to Expand at a Healthy Growth Rate…

Key Takeaways from the Pancreatic Endocrine Tumor Market Report Key Takeaways from the Pancreatic Endocrine Tumor Market Report Discover which therapies are expected to grab the major pancreatic endocrine tumor market share @Pancreatic Endocrine Tumor Market Report Pancreatic Endocrine Tumor Overview Pancreatic endocrine tumors (PETs) are a rare type of neoplasms that arise from the hormone-producing cells within the pancreas, known as the islet cells. These tumors can be...
PR Newswire
03/08/2023

Telesis Bio to Report Second Quarter Financial Results on Thursday, August 10…

Telesis Bio (Nasdaq: TBIO), a leader in automated multi-omic and synthetic biology solutions, today announced that it will release its second quarter 2023 financial results on Thursday, August 10, 2023, after the market closes. In conjunction with the release, management will host a conference call on Thursday, August 10, 2023, at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss the financial results and recent corporate highlights. The press release and live audio webcast can be...
Nasdaq GlobeNewswire
03/08/2023

Cellectis Provides Business Updates and Preliminary Financial Results for Second…

Updated clinical & translational data on BALLI-01 trial (evaluating UCART22 in r/r B-cell ALL) presented at the EHA annual meeting Clinical trials ongoing: BALLI-01 (evaluating UCART22), NATHALI-01 (evaluating UCART20x22) and AMELI-01 (evaluating UCART123) studies for patients with r/r B-cell ALL, r/r B-cell NHL and r/r AML, respectively Preclinical data presented on HBB gene correction of sickle cell mutation & TALE Base Editors (TALE-BE) at ISCT 2023 annual event...
Nasdaq GlobeNewswire
03/08/2023

Galapagos announces first half-year 2023 financial results

Half-year 2023 key financialsGroup revenues of €328.8 million Jyseleca® net sales of €54.3 million Cash and current financial investments of €3.9 billion on 30 June 2023Full year 2023 net sales guidance for Jyseleca® lowered to €100-€120 million – 2023 cash burn guidance of €380-€420 million reiteratedOncology pipeline update – continued progress with point-of-care manufactured CAR-T candidates in hemato-oncology, including approval of the clinical trial application in...
Nasdaq GlobeNewswire
03/08/2023

Press Release: U.S. CDC Advisory Committee unanimously recommends routine use of…

U.S. CDC Advisory Committee unanimouslyrecommends routine use ofBeyfortus™(nirsevimab-alip) to protect infants against RSV diseaseRecommendation for use in all infants below 8 months of age follows earlier than anticipated FDA approval and unanimous FDA Advisory Committee voteCommittee also voted unanimously to includeBeyfortusin the Vaccines for Children program, supporting equitable access for all eligible infants Beyfortus™is the first RSV...
Nasdaq GlobeNewswire
03/08/2023

Genmab Announces Financial Results for the First Half of 2023

August 3 , 2023 Copenhagen, Denmark; Interim Report for the First Six Months Ended June 30, 2023Highlights EPKINLY™ (epcoritamab-bysp) was approved by the U.S. Food and Drug Administration (U.S. FDA) as the first bispecific antibody to treat adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)Genmab and AbbVie Inc. (AbbVie) announced positive topline results from the Phase 1/2 EPCORE™ NHL-1 trial evaluating epcoritamab in patients with...
Nasdaq GlobeNewswire
03/08/2023

Medical Radiation Shielding Market worth $1.8 billion | MarketsandMarkets

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=124318639 Download an Illustrative overview:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=124318639 Browse in-depth TOC on "Medical Radiation Shielding Market" 142 - Tables 29 - Figures 200 - Pages Medical Radiation Shielding Market Scope: MRI Shielding Products segment is expected to account for the largest share in 2022. The Medical Radiation Shielding...
PR Newswire
03/08/2023

The Antibody Drug Conjugate Market is anticipated to grow at a CAGR of around…

The potential of an antibody drug conjugate for the treatment of various disease indications, including cancer, is being slowly recognized in the pharmaceutical sector. Specifically, the success of these products can be attributed to their ability to effectively identify and eliminate diseased cells, along with low risk of side effects. The potential of an antibody drug conjugate for the treatment of various disease indications, including cancer, is being slowly recognized in the pharmaceutical…
PR Newswire
03/08/2023

Study conducted by Leo Cancer Care indicates treating prostate patients with…

The study to investigate the positions and orientations of the male pelvic organs between the supine and upright positions focused on 15 volunteers aged 55-75. The study to investigate the positions and orientations of the male pelvic organs between the supine and upright positions focused on 15 volunteers aged 55-75. Each were scanned on a 0.6 T Fonar MRI scanner in the supine and upright positions with a full bladder and also with an empty bladder in the upright position. With a growing...
PR Newswire
03/08/2023

ERS Genomics & Transomic Technologies enter into CRISPR/Cas9 Licensing Agreement

Dr. Emmanuelle Charpentier, founder of ERS Genomics, received the 2020 Nobel Prize for the discovery of CRISPR/Cas9. As a direct outcome, the ERS patent portfolio stands as the definitive collection of proprietary rights to this gene editing technology. Dr. Emmanuelle Charpentier, founder of ERS Genomics, received the 2020 Nobel Prize for the discovery of CRISPR/Cas9. As a direct outcome, the ERS patent portfolio stands as the definitive collection of proprietary rights to this gene editing...
PR Newswire
03/08/2023
Altri  Comunicati